Protective effect of sevoflurane on glomerular glycocalyx filtration barrier during extracorporeal circulation

Protection of endothelial glycocalyx during extracorporeal circulation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300067723

Enrollment

Unknown

Registered

2023-01-19

Start date

2023-01-20

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal dysfunction

Interventions

Group A:sevoflurane

Group B:propofol

Eligibility

Sex/Gender

Male

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective cardiac surgery under extracorporeal circulation.

Exclusion criteria

Exclusion criteria: 1. Secondary surgery history; 2. Sandwich; 3. Pregnant women; 4. Hemodynamic instability (need to maintain vascular active drugs); 5. Severe liver disease (alanine aminotransferase and aspartate aminotransferase > 150 U); 6. Renal insufficiency (creatinine > 1.5 mg/dL); 7. Chronic obstructive pulmonary disease (forced expiratory volume in 1 second is less than 0.8 L); 8. Nervous system; 9. Carotid stenosis; 10. Severe infection patients (calcitonin > 0.5 ug/L, CRP is greater than 8.5).

Design outcomes

Primary

Measure	Time frame
urinary albumin to creatinine ratio;	—

Secondary

Measure	Time frame
glomerular filtration rate;glycocalyx;creatinine;Glomerular filtration barrier;Inflammatory index;Postoperative mechanical ventilation time;CCU hospital stay;hospital stay;KDIGO Score;	—

Countries

China

Contacts

Public ContactWeijian Wang

The First Affiliated Hospital of Wenzhou Medical University

wangwj2002@hotmail.com+86 13806683232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026